Pluristyx lands Fortune 500 backing in Series A, open until September 2
What's the deal? Seattle-based PluristyxDealroom has a profile for this one. Try Dealroom → announced the initial close of its Series A round, led by an unnamed global Fortune 500 company with participation from existing investors. The round remains open until September 2, 2026, to accommodate late-stage due diligence from other institutional and strategic investors. Financial terms were not disclosed.
What's the endgame? Pluristyx develops induced pluripotent stem cell (iPSC) technologies for the cell and gene therapy industry. The proceeds will fund inventory build and commercialization of its proprietary polyclonal stem cells, engineered for safety and universality across research, bioproduction, and manufacturing.
Why now? The raise follows what chief executive officer Benjamin FryerDealroom has a profile for this one. Try Dealroom → called a year of "commercial, technical, and regulatory breakthroughs." Pluristyx has launched its PluriForm product line for overnight suspension organoid manufacturing and secured patent allowances for its StemLoop mRNA reprogramming and iACT Stealth immune-cloaking technologies.
"We are excited to announce the successful Initial Close of our Series A round and deeply gratified by the validation from our new strategic investor," Fryer said. He added that the backing lets the company "rapidly expand our innovative platform" and "treat patients suffering from currently intractable diseases."
The context: This priced round extends a steady capital build-out. Pluristyx closed oversubscribed rounds in late 2023 and mid-2025, the latter including a $2 million convertible note investment from BioLife SolutionsDealroom has a profile for this one. Try Dealroom →, which secured board and acquisition rights in July 2025. Its investor base also includes BroadOak Capital PartnersDealroom has a profile for this one. Try Dealroom →.
What could go wrong? With no disclosed amount or valuation, the round's scale is hard to gauge — whether it marks a step change or a continuation of Pluristyx's existing funding trajectory. The named lead, a Fortune 500 strategic, remains undisclosed until the round closes.
The signal: A priced Series A anchored by a large multinational adds a marquee strategic to a sector-focused investor base, a validation signal for iPSC platform providers courting the cell and gene therapy market. For Pluristyx, it also hints at a potential route to deeper commercial ties or M&A.
Read more: StreetInsider
Image credit: NIH-NCATS
